Get started
Author

Lilla Hámori

Observed names: Hámori, Lilla, Lilla Hamori, Lilla, HÁMORI
ORCID: 0000-0002-8962-0040
Observed ORCID: 0000-0002-8962-0040
OpenAlex ID: A5084585441
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer
2017 · András Füredi, Kornélia Szebényi, et al. · Journal of Controlled Release · 103
Absence of the Tks4 Scaffold Protein Induces Epithelial-Mesenchymal Transition-Like Changes in Human Colon Cancer Cells
2019 · Bálint Szeder, Júlia Tárnoki-Zách, et al. · Cells · 22
PDF
Establishment and Characterization of a Brca1−/−, p53−/− Mouse Mammary Tumor Cell Line
2020 · Lilla Hámori, Gyöngyi Kudlik, et al. · International Journal of Molecular Sciences · 19
PDF
Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines
2022 · Szonja Polett Pósa, Gyula Dargó, et al. · Bioorganic & Medicinal Chemistry · 17
PDF
Development of non-invasive, bioimpedance-based measuring device for primary tumor detection
2021 · Zoltan Vizvari, Nina Gyorfi, et al. · IEEE International Symposium on Computational Intelligence and Informatics (CINTI)
[Development of novel treatment strategies for drug resistant cancer].
2021 · Flóra Vajda, Eszter Bajtai, et al. · PubMed
Potenciális bioaktivitással rendelkező cinkona alapú organokatalizátorok vizsgálata
2020 · Pósa Szonja Polett, Gyula Dargó, et al.
Potenciális bioaktivitással rendelkező cinkona alapú organokatalizátorok vizsgálata: Study of cinchona-based organocatalysts with potential bioactivity
2020 · Szonja Polett, PÓSA, Gyula, DARGÓ, et al. · Nemzetközi Vegyészkonferencia
[Relevance of animal models in the development of compounds targeting multidrug resistant cancer].
2015 · András Füredi, Szilárd Tóth, et al. · PubMed
Works count: 10
Citation count: 161
H-index: 4
I10-index: 4
Year
Topic
Type